FDA’s Benefit-Risk Templates for Drug Reviews Lack Patient Input Process: NORD

Drug Industry Daily
A A
The FDA’s draft plan for implementing standard benefit-risk templates in drug reviews lacks a process for including patient concerns, the National Organization of Rare Diseases (NORD) says.

To View This Article:

Login

Subscribe To Drug Industry Daily